Becton, Dickinson and Company $BDX Shares Acquired by Focus Financial Network Inc.

Focus Financial Network Inc. boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,634 shares of the medical instruments supplier’s stock after purchasing an additional 138 shares during the quarter. Focus Financial Network Inc.’s holdings in Becton, Dickinson and Company were worth $454,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the business. DLK Investment Management LLC boosted its position in Becton, Dickinson and Company by 5.5% during the 2nd quarter. DLK Investment Management LLC now owns 21,946 shares of the medical instruments supplier’s stock worth $3,780,000 after acquiring an additional 1,148 shares during the period. Pines Wealth Management LLC boosted its position in Becton, Dickinson and Company by 22.9% during the 2nd quarter. Pines Wealth Management LLC now owns 1,752 shares of the medical instruments supplier’s stock worth $309,000 after acquiring an additional 327 shares during the period. Pallas Capital Advisors LLC boosted its position in Becton, Dickinson and Company by 197.2% during the 2nd quarter. Pallas Capital Advisors LLC now owns 6,607 shares of the medical instruments supplier’s stock worth $1,138,000 after acquiring an additional 4,384 shares during the period. Financiere des Professionnels Fonds d investissement inc. boosted its position in Becton, Dickinson and Company by 11.4% during the 2nd quarter. Financiere des Professionnels Fonds d investissement inc. now owns 101,333 shares of the medical instruments supplier’s stock worth $17,455,000 after acquiring an additional 10,355 shares during the period. Finally, Czech National Bank boosted its position in Becton, Dickinson and Company by 6.2% during the 2nd quarter. Czech National Bank now owns 70,056 shares of the medical instruments supplier’s stock worth $12,067,000 after acquiring an additional 4,106 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Activity

In related news, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Claire Fraser sold 917 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the transaction, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 2,965 shares of company stock valued at $551,536 in the last three months. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Stock Performance

BDX opened at $187.27 on Friday. The company has a market cap of $53.68 billion, a PE ratio of 33.68, a price-to-earnings-growth ratio of 1.51 and a beta of 0.27. The stock has a 50-day moving average of $187.65 and a 200-day moving average of $190.16. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.28. The company had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm’s revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company’s payout ratio is currently 74.82%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on BDX. Morgan Stanley boosted their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Argus boosted their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Barclays dropped their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 3rd. Finally, Wells Fargo & Company boosted their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research note on Friday, August 8th. Four investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $213.30.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.